Blood glucose profiles in diabetic rodents using different insulin preparations.
The aim of the present study was to evaluate several long-acting insulin preparations for their ability to normalize the blood glucose profile of rats and mice with streptozocin-induced diabetes mellitus. The single injection of a long-acting zinc insulin (CAS 8049-62-5) suspension or insulin glargine (CAS 160337-95-1) in both species induced a steep to moderate fall in blood glucose concentration. Blood glucose was then normalized for 2-3 h, until 3 h after insulin injection blood glucose concentration tended towards levels before insulin application. In contrast, implants produced with a mixture of human insulin and palmitic acid micro-crystals normalized blood glucose profile over 24 h in both species at least 30 days after implantation. Therefore, these implants with a sustained release of insulin are suitable to control the blood glucose in diabetic rats and mice.
Schneider
Swetlana
S
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen, Tübingen, Germany.
Weber
Renate
R
Luippold
Gerd
G
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004343:Drug Implants; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D017207:Rats, Sprague-Dawley; D013535:Suspensions
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D004343:Drug Implants; D007004:Hypoglycemic Agents; D007328:Insulin; D013535:Suspensions